- Home
- ARWR vs GLPG Comparison
ARWR vs GLPG Comparison
Compare ARWR & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- GLPG
- Stock Information
- Founded
- ARWR 2003
- GLPG 1999
- Country
- ARWR United States
- GLPG Belgium
- Employees
- ARWR N/A
- GLPG N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- ARWR Health Care
- GLPG Health Care
- Exchange
- ARWR Nasdaq
- GLPG Nasdaq
- Market Cap
- ARWR 1.8B
- GLPG 1.8B
- IPO Year
- ARWR 1993
- GLPG 2005
- Fundamental
- Price
- ARWR $15.32
- GLPG $27.42
- Analyst Decision
- ARWR Buy
- GLPG Sell
- Analyst Count
- ARWR 8
- GLPG 4
- Target Price
- ARWR $43.71
- GLPG $25.33
- AVG Volume (30 Days)
- ARWR 1.5M
- GLPG 263.3K
- Earning Date
- ARWR 08-07-2025
- GLPG 07-23-2025
- Dividend Yield
- ARWR N/A
- GLPG N/A
- EPS Growth
- ARWR N/A
- GLPG N/A
- EPS
- ARWR N/A
- GLPG N/A
- Revenue
- ARWR $545,209,000.00
- GLPG $311,493,731.00
- Revenue This Year
- ARWR $21,924.50
- GLPG $0.78
- Revenue Next Year
- ARWR N/A
- GLPG N/A
- P/E Ratio
- ARWR N/A
- GLPG N/A
- Revenue Growth
- ARWR 1436.97
- GLPG 18.32
- 52 Week Low
- ARWR $9.57
- GLPG $22.36
- 52 Week High
- ARWR $30.41
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- ARWR 46.47
- GLPG 44.30
- Support Level
- ARWR $15.19
- GLPG $27.67
- Resistance Level
- ARWR $16.06
- GLPG $29.28
- Average True Range (ATR)
- ARWR 0.68
- GLPG 0.57
- MACD
- ARWR -0.23
- GLPG -0.19
- Stochastic Oscillator
- ARWR 15.23
- GLPG 13.10
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.